Skip to main content
SpringerLink
Log in

Inzidenz der Faktor VIII-Hemmkörperentwicklung bei Hämophilie-Patienten und kumulatives Risiko in Abhängigkeit von Alter und Substitutionstherapie. Ergebnisse einer 15jährigen Longitudinal-Studie

  • Conference paper
Book cover 22. Hämophilie-Symposion Hamburg 1991

  • 18 Accesses

Zusammenfassung

Die Entwicklung von IgG-Antikörpern gegen substituierten Faktor VIII: C, bleibt trotz der vielen neuen Erkenntnisse auf dem Gebiet ihrer molekularbiologischen Eigenschaften weiterhin ein gravierendes und bisher ungelöstes Problem der Hämophiliebehandlung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Biggs R (1974) Jaundice and antibodies directed against factors VIII and IX in patients treated for haemophilia or Christmas disease in the United Kingdom. Br J Haematol 26:313–329

    Article  PubMed  CAS  Google Scholar 

  2. Brinkhous KM, Roberts HR, Weiss AE (1972) Prevalence of inhibitors in hemophilia A and B. Thromb Diath Haemorrh Suppl 51:315–321

    Google Scholar 

  3. Gill FM, Shapiro SS, Poole WK.et al (1984) The natural history of factor VIII inhibitors in patients with Hemophilia A. In: Hoyer LW (ed) „Factor VIII Inhibitors. “ New York: Alan R Liss, Inc, p 19

    Google Scholar 

  4. Ikkala E, Simonen O (1971) Factor VIII inhibitors and the use of blood products in patients with haemophilia A. Scand J Haemat 8:16–20

    Article  PubMed  CAS  Google Scholar 

  5. Kasper CK (1973) Incidence and course of inhibitors among patients with classic haemophi­lia. Thrombo Diath Haemorrh 30:263–271

    CAS  Google Scholar 

  6. Schwartz RS, Abildgaard CF, Aledort LM et al (1990) Human recombinant DNA-derived antihemophilic factor (F VIII) in the treatment of hemophilia A. N Engl J Med 323:1799–1805

    Google Scholar 

  7. Schwarzinger I, Pabinger I, Korninger C et al (1987) Incidence of Inhibitors in Patients with Severe and Moderate Hemophilia A Treated with Factor VIII Concentrates. American J of Hematology 24:241–245

    Article  CAS  Google Scholar 

  8. Strauss HS (1969) Aquired circulating anticoagulants in hemophilia A. N Engl J Med 281:886–873

    Google Scholar 

  9. Allain JP, Frommel D (1976) Antibodies to Factor VIII. V. Patterns of Immune Response to Factor VIII in Hemophilia A. Blood 47:973

    Google Scholar 

  10. Ruggeri ZM (1977). Natural history of 39 factor VIII inhibitors in hemophilias. In: Work­shop on Inhibitors of Factors VIII and IX. Facultas-Verlag Wien, p 45–48

    Google Scholar 

  11. Shapiro SS (1979) Antibodies to blood coagulation factors. Clinics in Haematology 8:207–214

    PubMed  CAS  Google Scholar 

  12. Shapiro SS, Hultin M (1975) Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemost 1:336

    Google Scholar 

  13. Langdell RD, Wagner RH, Brinkhous KM (1953) Effect of antihaemophilic factor on one-stage-clotting test: A presumptive test for haemophilia and a simple one-stage antihae­mophilic factor assay procedure. J Lab Clin Med 41:637–645

    Google Scholar 

  14. Kasper CK, Aledort LM, Counts RB et al (1975) A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869

    Google Scholar 

  15. Kaplan EL, Meier (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  16. Ikkala E, Helske T, Myllyläg G et al (1982) Changes in the life-expectancy of patients with severe haemophilia A in Finland in 1930–1979. Br J Haematol 52:7–12

    Article  PubMed  CAS  Google Scholar 

  17. Rizza CR, Spooner RJD (1983) Treatment of hemophilia and related disorders in Britain and Northern Ireland during 1976–1980: Report on behalf of the directors of hemophilia centres in the United Kingdom. Br Med J 286:929

    Google Scholar 

  18. Larsson SA (1985) Life expectancy of Swedish haemophiliacs 1831–1980. Br J Haematol 59:593–602

    Article  PubMed  CAS  Google Scholar 

  19. Rosendaal FR, Varekamp I, Smit C et al (1989) Mortality and causes of death in Dutch hemophiliacs 1973–1986. Br J Haematol 71:71–76

    Article  PubMed  CAS  Google Scholar 

  20. Mc Millan CW, Shapiro SS, Whitehurst D et al (1988) The natural history of factor VIII inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII: C inhibitors. N Engl J Med 71:344–348

    Google Scholar 

  21. Rasi V, Ikkala E (1990) Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 76:369–371

    Article  PubMed  CAS  Google Scholar 

  22. Shapiro SS (1984) Markers for the Factor VIII Antibody Response in Hemophilia A. Scand J Haematol-Suppl 40:33, 181 –185

    PubMed  CAS  Google Scholar 

  23. Kesteven PJ, Holland LJ, Lawrie AS et al (1984) Inhibitor to Faktor VIII in Mild Hemophilia. Thromb Haemostas 52:50–52

    CAS  Google Scholar 

  24. Stenbjerg S, Ingerslev J, Zachariae E (1984). Factor VIII inhibitor treatment with high doses of factor VIII. Thrombosis Research 34:533–539

    Article  PubMed  CAS  Google Scholar 

  25. Kreuz W, Ehrenforth S, Scharrer I et al (1991) Factor VIII inhibitors in children with haemophilia. Long-term longitudinal results of dose-dependent induced immunotolerance. Annals of Hematol 62: A 46

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Frankfurt/Main, Deutschland

    S. Ehrenforth, W. Kreuz, R. Linde, D. Menzer, T. Beeg & I. Scharrer

Authors
  1. S. Ehrenforth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Kreuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Linde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Menzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Beeg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. Scharrer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Humberg, Deutschland

    G. Landbeck

  2. Abteilung für Angiologie, Universitätsklinikum, Theodor-Stern-Kai 7, 6000, Frankfurt am Main 70, Deutschland

    Inge Scharrer

  3. Hämostaseologische Abteilung Med. Klinik Innenstadt, Ziemssenstraße 1, 8000, München 2, Deutschland

    Wolfgang Schramm

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Ehrenforth, S., Kreuz, W., Linde, R., Menzer, D., Beeg, T., Scharrer, I. (1992). Inzidenz der Faktor VIII-Hemmkörperentwicklung bei Hämophilie-Patienten und kumulatives Risiko in Abhängigkeit von Alter und Substitutionstherapie. Ergebnisse einer 15jährigen Longitudinal-Studie. In: Landbeck, G., Scharrer, I., Schramm, W. (eds) 22. Hämophilie-Symposion Hamburg 1991. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77881-0_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77881-0_35

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-56096-8

  • Online ISBN: 978-3-642-77881-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation